RxDoctor Payments Data

Rebekah Vandewalle

Family · Green Bay, WINPI 1770030157

Payments from drug & device makers

$1,507in general payments, 2019–2025

Across 56 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$350
  • Biogen$238
  • Livanova USA, Inc.$152
  • Novartis$90
  • Medtronic$72
  • Kyowa Kirin, Inc.$59
  • plus $548 from 22 others

What the payments were for

  • Consulting fees$15010%
  • Food & beverage$1,35790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,507 in reported general payments places this provider in the 85th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$169,698
Medicare patients
260
Services billed
19,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5030$965,797
VumerityDiroximel Fumarate19$177,120
Kesimpta PenOfatumumab18$175,951
NuplazidPimavanserin Tartrate29$146,763
Nurtec OdtRimegepant Sulfate74$98,520
Emgality PenGalcanezumab-Gnlm89$71,884
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$69,503
Aimovig AutoinjectorErenumab-Aooe70$63,689
GlatopaGlatiramer Acetate23$48,339
LamictalLamotrigine28$25,050
Carbidopa-LevodopaCarbidopa/Levodopa701$22,629
Memantine Hcl460$20,680
RytaryCarbidopa/Levodopa28$18,281
Ajovy AutoinjectorFremanezumab-Vfrm19$18,052
AptiomEslicarbazepine Acetate11$16,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$238$177,12019 claims
PfizerNurtec Odt$18$98,52074 claims
AbbVieQulipta, Ubrelvy$350$23,63224 claims
UCB, Inc.Vimpat$19$8,95412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,273 family providers in Wisconsin.

Other family in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →